Denosumab HALT 13862
|
1468 |
Castration-sensitive, current androgen-deprivation therapy; no metastases; high risk for fracture |
Denosumab 60 mg versus placebo, every 6 months for 3 years |
Significant increase in bone mineral density; significant 62% reduction in 3-year incidence of new vertebral fractures |
Toremifene Protocol G30020363
|
1389 |
Castration-sensitive, current androgen-deprivation therapy; high risk for fracture |
Toremifene 80 mg daily oral versus placebo |
Fewer new vertebral fractures (2.5% vs. 4.9%; P < .05); increased bone mineral density, decreased breast pain, decreased hot flashes, favorable lipid profile changes |